SupplementaryFig S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Year: 2026
Type: supplementary-materials
Abstract: Figure S2 shows biochemical potency of enozertinib compared to other EGFR inhibitors.
Authors: Melissa R. Junttila, Claire E. Repellin, Sumeet Salaniwal, Robert Warne, Younho Lee, Haelee Kim, Kyung Ah Seo, Youngyi Lee, Hong-ryul Jung, Jason Baik, Jae H. Chang, Gina Andreatta, Jason E. Long, Jessica D. Sun, Stephanie W. Ni, Liliana Soroceanu, Lidia C. Sambucetti, Akash Das, Brenda Chan, Padmini Narayanan, Ashley S. Pereira, Edna Chow Maneval, Pratik S. Multani, Rupal Patel, Matt Panuwat, Brian R. Blank, Chudi Ndubaku, F. Anthony Romero, Anneleen Daemen, Alexander I. Spira, Lori S. Friedman
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7127098135